Compare · BDX vs VTAK
BDX vs VTAK
Side-by-side comparison of Becton Dickinson and Company (BDX) and Catheter Precision Inc. (VTAK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and VTAK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.32B, about 17302.4x VTAK ($2.5M).
- Over the past year, BDX is down 25.7% and VTAK is down 83.7% - BDX leads by 58.0 points.
- BDX has been more active in the news (9 items in the past 4 weeks vs 8 for VTAK).
- BDX has more recent analyst coverage (25 ratings vs 0 for VTAK).
- Company
- Becton Dickinson and Company
- Catheter Precision Inc.
- Price
- $152.11-1.77%
- $0.90-3.09%
- Market cap
- $43.32B
- $2.5M
- 1M return
- -3.89%
- -22.71%
- 1Y return
- -25.68%
- -83.67%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- AMEX
- IPO
- 2018
- News (4w)
- 9
- 8
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- BD Earns Industry Top Honors for Transparency, Resiliency and Partnership
- Goldman resumed coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- BD to Announce Financial Results for its Second Quarter of Fiscal 2026
- Rick Byrd to Retire from BD
- For Women Managing Nighttime Incontinence, Better Sleep and Comfort Start with BD® PureWick® Urine Collection System
- BD Delivers Next‑Generation TIPS Innovation to Advance Portal Hypertension Care Across the European Union
- When Every Beat Matters, BD Helps Clinicians Eliminate Blind Spots with Continuous, Noninvasive Blood Pressure Insight
- SEC Form 4 filed by Neal Shana Carol
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest VTAK
- Catheter Precision Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Catheter Precision Secures U.S. Patent Allowance on Foundational Surgical Technology, Establishing Powerful IP and Accelerating Scalable Growth Strategy
- FLYTE EMERGES AS DIRECT BENEFICIARY AS RISING FUEL COSTS DRIVE AIRLINE RETREAT FROM SHORT-HAUL ROUTES
- VTAK Definitive Agreement to Acquire 100% of Fly Flyte Inc. Obtains Shareholder Approval
- Catheter Precision Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Catheter Precision Announces Accepted Publication in Leading European Medical Journal
- Catheter Precision to Attend the Annual European Heart Rhythm Association Conference
- New LockeT Data Accepted in Leading Electrophysiology Journal
- Catheter Precision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Catheter Precision Inc.